Testosterone Recovery and IAD Therapy for Prostate Cancer
Testosterone Recovery and IAD Therapy for Prostate Cancer
This study with the 3-month 11.25 mg depot microcapsule formulation of leuprorelin acetate shows a real achievement of intermittent castration with normalisation of testosterone levels during off-treatment periods. It is assumed that the recovery of testosterone in IAD patients will balance the benefits of long-term androgen withdrawal and reduce ADT- related side effects. IAD seems to be a feasible option in selected well-informed and compliant patients who need long-term hormonal deprivation.
Conclusion
This study with the 3-month 11.25 mg depot microcapsule formulation of leuprorelin acetate shows a real achievement of intermittent castration with normalisation of testosterone levels during off-treatment periods. It is assumed that the recovery of testosterone in IAD patients will balance the benefits of long-term androgen withdrawal and reduce ADT- related side effects. IAD seems to be a feasible option in selected well-informed and compliant patients who need long-term hormonal deprivation.